What should be done for a 17‑year‑old patient who is taking the maximum approved dose of Qelbree (viloxazine) 400 mg daily but still has inadequate focus and attention?

Switch to a Stimulant Medication

For a 17-year-old on maximum-dose Qelbree (400 mg) without adequate response, you should switch to an FDA-approved stimulant medication, which has the strongest evidence for efficacy in adolescent ADHD. 1

Rationale for Switching

The American Academy of Pediatrics guidelines explicitly state that for adolescents (12-18 years), clinicians should prescribe FDA-approved medications for ADHD, with particularly strong evidence for stimulant medications compared to non-stimulants 1. The evidence hierarchy shows stimulants have superior efficacy over atomoxetine, extended-release guanfacine, and extended-release clonidine (in that order) 1.

Since this patient is already on the maximum approved dose of viloxazine (400 mg for adolescents) 2 and experiencing inadequate symptom control, continuing to optimize a non-stimulant with weaker evidence makes little clinical sense when more effective options exist.

Specific Medication Recommendations

First-line stimulant options include:

• Long-acting methylphenidate preparations (e.g., Concerta, extended-release formulations)
• Long-acting amphetamine preparations (e.g., lisdexamfetamine/Vyvanse, mixed amphetamine salts XR)

These provide once-daily dosing with coverage throughout the school day and into evening hours—critical for a 17-year-old who may be driving 1. Longer-acting formulations also reduce diversion risk, which is a particular concern in adolescents 1.

Important Pre-Treatment Screening

Before initiating stimulant therapy, assess for:

• Substance use symptoms or history - if present, address this first before treating ADHD 1
• Personal or family history of cardiac disease - obtain cardiovascular history
• Baseline heart rate and blood pressure 2
• Symptoms of anxiety, depression, or suicidal ideation 3

Alternative Non-Stimulant Options (If Stimulants Contraindicated)

If stimulants are contraindicated or refused, consider:

1. Atomoxetine - has more robust evidence than other non-stimulants 1, though recent data suggest viloxazine may be more effective and better tolerated than atomoxetine 4

2. Extended-release guanfacine or clonidine - these have less evidence for inattention but can help with hyperactivity/impulsivity 1

Why Not Continue Optimizing Viloxazine?

The patient is already at the maximum FDA-approved dose for adolescents (400 mg) 2. The FDA label explicitly states the maximum for ages 12-17 is 400 mg daily, with higher doses (up to 600 mg) only approved for adults 2. Dose-response meta-analysis shows that doses above 400 mg may not provide additional efficacy and follow a bell-shaped curve 5. Additionally, viloxazine's effect typically plateaus by weeks 4-6 5, so if there's inadequate response at maximum dose after this timeframe, further waiting is unlikely to help.

Behavioral Interventions

While medication adjustment is the priority, consider adding or optimizing behavioral therapy if not already in place 1. The guidelines recommend both medication and behavioral interventions preferably together for adolescents, though the evidence for behavioral therapy alone in this age group is weaker (Grade C) compared to medication (Grade A) 1.

Common Pitfalls to Avoid

• Don't underdose stimulants - titrate to maximum benefit with minimum adverse effects 1
• Don't assume non-response to one medication class predicts non-response to another - stimulants have a different mechanism and ~70% response rate 6
• Don't forget to reassess comorbidities - anxiety, depression, learning disabilities, or sleep disorders may be contributing to apparent treatment resistance 1, 3
• Monitor for diversion - particularly important in adolescents; consider formulations with lower abuse potential if concerned 1